Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial.
Adult
Blood Glucose
/ drug effects
Circadian Rhythm
Cross-Over Studies
Diabetes Mellitus, Type 1
/ blood
Double-Blind Method
Drug Administration Schedule
Female
Humans
Hypoglycemia
/ chemically induced
Hypoglycemic Agents
/ administration & dosage
Insulin
/ administration & dosage
Insulin Aspart
/ administration & dosage
Insulin Infusion Systems
Male
Meals
Postprandial Period
Young Adult
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
03
05
2019
accepted:
03
09
2019
pubmed:
3
10
2019
medline:
3
10
2020
entrez:
3
10
2019
Statut:
ppublish
Résumé
We evaluated the safety and efficacy of day-and-night fully closed-loop insulin therapy using faster (Faster-CL) compared with standard insulin aspart (Standard-CL) in young adults with type 1 diabetes. In a double-blind, randomized, crossover trial, 20 participants with type 1 diabetes on insulin pump therapy (11 females, aged 21.3 ± 2.3 years, HbA The proportion of TIR was similar for both arms: 53.3% (83% overnight) in Faster-CL and 57.9% (88% overnight) in Standard-CL ( Fully closed-loop insulin delivery using either faster or standard insulin aspart was safe and efficient in achieving near-normal glucose concentrations outside postprandial periods. The closed-loop algorithm was better adjusted to the standard insulin aspart.
Identifiants
pubmed: 31575640
pii: dc19-0895
doi: 10.2337/dc19-0895
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Insulin Aspart
D933668QVX
Banques de données
ClinicalTrials.gov
['NCT03212950']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
29-36Informations de copyright
© 2019 by the American Diabetes Association.